Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355567 | 1.00 | GPR119 (0.52) | GPR119CYP3A4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1128505 | 1.00 | GPR119 (0.52) | GPR119CYP3A4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1128575 | 0.88 | GPR119 (0.56) | GPR119CYP3A4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL4359294 | 0.80 | GPR119 (0.43) | GPR119CYP3A4 | |
| SCHEMBL390258 | 0.80 | GPR119 (0.63) | GPR119CYP3A4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1128747 | 0.80 | CYP3A4 (0.53) | GPR119CYP3A4CYP2C9KCNH2 | |
| SCHEMBL4454207 | 0.80 | GPR119 (0.46) | GPR119CYP3A4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL4459757 | 0.80 | GPR119 (0.46) | GPR119CYP3A4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1129187 | 0.77 | CYP3A4 (0.61) | GPR119CYP3A4CYP2C9KCNH2 | |
| SCHEMBL1128363 | 0.77 | GPR119 (0.66) | GPR119CYP3A4CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | claimed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | claimed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | GPR119 1/4885CYP3A4 1503/4885CYP2C19 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.